Regeneron 4th-qrt misses expectations, despite 37% sales growth

9 February 2016

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) this morning reported fourth-quarter 2015 financial results, posting non-generally accepted accounting principles (GAAP) earnings per share of $2.83, up 1%, on revenues up 37% to $1.10 billion. This compares to consensus estimates from Thomson Reuters of $3.36 in EPS on revenue of $1.17 billion.

For the full year, total revenues were 46% higher at $4.10 billion, with non-GAAP earnings per share up 10% at $12.07, and non-GAAP net income 19% higher year-on-year at $1.40 billion. Regeneron’s shares were down 5.76% at $368.97 by 10.58 EST.

Strong sales growth seen for Eylea in 2015, but 2016 expected to slow

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK